Postoperative Insulin Infusion Omission After Pancreatectomy NCT07540975

← ClinicalTrials.gov Studies

Postoperative Insulin Intervention After Pancreatectomy in nDM Patients

N/A NCT07540975 Kind: NA Apr 21, 2026

Abstract

The goal of this randomized non-inferiority clinical trial is to evaluate whether routine postoperative insulin infusion can be safely omitted in preoperative non-diabetic adult patients undergoing pancreatectomy for periampullary or pancreatic tumors. The primary purpose is to determine whether withholding insulin infusion provides comparable glycemic control while reducing treatment-related burden and adverse events.

The main questions it aims to answer are:

• Does omission of postoperative insulin infusion result in non-inferior mean blood glucose levels through postoperative day (POD) 3 compared to standard insulin infusion?
• Does omission of insulin infusion reduce the incidence of hypoglycemia without increasing postoperative complications, including surgical site infection within 3 months?

Researchers will compare a no-insulin infusion group (intervention arm) with a standard insulin infusion group (control arm) to determine whether avoiding routine insulin infusion maintains comparable glycemic control while improving safety and patient comfort.

Participants will:

• Undergo pancreatectomy and be randomly assigned (1:1) to either receive standard insulin infusion or no routine insulin infusion postoperatively
• Have blood glucose monitored using intermittent testing and continuous glucose monitoring (flash glucose monitoring system)
• Receive protocol-based glycemic management, including rescue insulin if hyperglycemia occurs or discontinuation if hypoglycemia...

Conditions: Postoperative Hyperglycemia, Pancreatectomy

Interventions: Insulin Infusion, No Insulin Infusion (Standard Monitoring Only)

View original document →